The recent approval of Biogen Inc’s (NASDAQ:BIIB) high-price Alzheimer’s drug is raising questions about who will have access to the $56,000/year treatment…
BMO Capital analyst Matt Borsch maintains Centene (NYSE: CNC) with a Outperform and raises the price target from $88 to $93.BMO Capital analyst Matt Borsch maintains Centene (NYSE:CNC) with a Outperform and raises the price target from $88 to $93.
Truist Securities analyst David Macdonald maintains Centene (NYSE: CNC) with a Buy and raises the price target from $80 to $90.Truist Securities analyst David Macdonald maintains Centene (NYSE:CNC) with a Buy and raises the price target from $80 to $90.
Piper Sandler raised Patterson Companies, Inc. (NASDAQ: PDCO) price target from $34 to $44. Patterson Companies shares rose 4% to $36.82 in pre-market trading.